Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Dow
Express Scripts
Johnson and Johnson
Harvard Business School

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

Claims for Patent: 8,247,397

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,247,397
Title:Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
Abstract: Combinations of PI3K inhibitor compounds having Formulas I and II and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hyperproliferative disorders such as cancer. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. ##STR00001##
Inventor(s): Belvin; Marcia (South San Francisco, CA), Friedman; Lori (South San Francisco, CA), Hoeflich; Klaus (San Mateo, CA), Sampath; Deepak (San Francisco, CA), Vijapurkar; Ulka (Millbrae, CA), Wallin; Jeffrey (Berkeley, CA), Johnson; Leisa (Point Richmond, CA), Singh; Mallika (San Francisco, CA), Patel; Sonal (Slough, GB)
Assignee: Genentech, Inc. (South San Francisco, CA) F. Hoffman-La Roche AG (Basel, CH)
Application Number:12/208,227
Patent Claims:1. A method for the treatment of comprising administering a therapeutic combination as a combined formulation or by alternation to a mammal, wherein the therapeutic combination comprises a therapeutically effective amount of a compound having Formula I or II, and a therapeutically effective amount of a chemotherapeutic agent selected from erlotinib, docetaxel, 5-FU, gemcitabine, PD-0325901, cisplatin, carboplatin, paclitaxel, bevacizumab, trastuzumab, pertuzumab, temozolomide, tamoxifen, doxorubicin, Akti-1/2 , HPPD, rapamycin, and lapatinib; where Formulas I and II are: 4-(2-(1H-indazol-4-yl)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)thieno- [3,2-d]pyrimidin-4-yl)morpholine having Formula Ia: ##STR00065## or (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]py- rimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one having Formula Ib: ##STR00066## or stereoisomers, geometric isomers, tautomers, or pharmaceutically acceptable salts thereof.

2. The method of claim 1 wherein the chemotherapeutic agent is erlotinib.

3. The method of claim 1 wherein the chemotherapeutic agent is docetaxel.

4. The method of claim 1 wherein the chemotherapeutic agent is 5-FU.

5. The method of claim 1 wherein the chemotherapeutic agent is gemcitabine.

6. The method of claim 1 wherein the chemotherapeutic agent is PD-0325901.

7. The method of claim 1 wherein the chemotherapeutic agent is cisplatin.

8. The method of claim 1 wherein the chemotherapeutic agent is carboplatin.

9. The method of claim 1 wherein the chemotherapeutic agent is paclitaxel.

10. The method of claim 1 wherein the chemotherapeutic agent is bevacizumab.

11. The method of claim 1 wherein the chemotherapeutic agent is trastuzumab.

12. The method of claim 1 wherein the chemotherapeutic agent is pertuzumab.

13. The method of claim 1 wherein the chemotherapeutic agent is temozolomide.

14. The method of claim 1 wherein the chemotherapeutic agent is tamoxifen.

15. The method of claim 1 wherein the chemotherapeutic agent is doxorubicin.

16. The method of claim 1 wherein the chemotherapeutic agent is Akti-1/2.

17. The method of claim 1 wherein the chemotherapeutic agent is HPPD.

18. The method of claim 1 wherein the chemotherapeutic agent is rapamycin.

19. The method of claim 1 wherein the chemotherapeutic agent is lapatinib.

20. The method of claim 1 where the Formula I or II compound is 4-(2-(1H-indazol-4-yl)-6-((4-(methylsulfonyppiperazin-1-yl)methyl)thieno[- 3,2-d]pyrimidin-4-yl)morpholine having Formula Ia: ##STR00067##

21. The method of claim 1 where the Formula I or II compound is (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]py- rimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one having Formula Ib: ##STR00068##

22. The method of claim 1 wherein the pharmaceutically acceptable salt of the Formula I or II compound is selected from a salt formed with hydrochloric acid, hydrobromic acid, hydroiodic acid, sulphuric acid, nitric acid, phosphoric acid, methanesulfonic acid, benzenesulphonic acid, formic acid, acetic acid, trifluoroacetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, ethanesulfonic acid, aspartic acid and glutamic acid.

23. The method of claim 1 wherein the therapeutically effective amount of a compound having Formula I or II, and the therapeutically effective amount of the chemotherapeutic agent are administered as a combined formulation.

24. The method of claim 1 wherein the therapeutically effective amount of a compound having Formula I or II, and the therapeutically effective amount of the chemotherapeutic agent are administered to a mammal by alternation.

25. The method of claim 24 wherein the mammal is administered with the chemotherapeutic agent and subsequently administered with the Formula I or II compound.

26. The method of claim 24 wherein the therapeutic combination is administered by a dosing regimen where the therapeutically effective amount of a compound having Formula I or II is administered in a range from twice daily to once every three weeks, and the therapeutically effective amount of the chemotherapeutic agent is administered in a range from twice daily to once every three weeks.

27. The method of claim 26 wherein the dosing regimen is repeated one or more times.

28. The method of claim 1 wherein administration of the therapeutic combination results in a synergistic effect.

29. The method of claim 1 wherein the is cancer selected from breast, cervical, colon, endometrial, glioma, lung, melanoma, ovarian, pancreatic, and prostate.

30. The method of claim 29 wherein the cancer expresses a K-ras mutant.

31. The method of claim 24 wherein the mammal is a breast cancer patient wherein the patient is HER2 negative, ER (estrogen receptor) negative, and PR (progesterone receptor) negative.

32. The method of claim 31 wherein the patient is administered Formula Ia and docetaxel.

33. The method of claim 1 wherein the Formula I or II compound and the chemotherapeutic agent are each administered in an amount from about 1 mg to about 1000 mg per unit dosage form.

34. The method of claim 1 wherein the Formula I or II compound and the chemotherapeutic agent are administered in a ratio of about 1:50 to about 50:1 by weight.

Details for Patent 8,247,397

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Request a Trial Genentech, Inc. (South San Francisco, CA) F. Hoffman-La Roche AG (Basel, CH) 2036-04-30 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Request a Trial Genentech, Inc. (South San Francisco, CA) F. Hoffman-La Roche AG (Basel, CH) 2036-04-30 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Request a Trial Genentech, Inc. (South San Francisco, CA) F. Hoffman-La Roche AG (Basel, CH) 2036-04-30 RX search
Genentech PERJETA pertuzumab VIAL; SINGLE-USE 125409 001 2012-06-08   Request a Trial Genentech, Inc. (South San Francisco, CA) F. Hoffman-La Roche AG (Basel, CH) 2036-04-30 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
AstraZeneca
Baxter
Johnson and Johnson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.